EDAP TMS S.A., trading on NASDAQ under the symbol EDAP, specializes in medical devices, particularly in the field of High-Intensity Focused Ultrasound (HIFU) technology. The company is known for its Focal One® System, which is used in treating prostate cancer. EDAP competes with other medical device companies in the HIFU space, focusing on innovation and expanding its market presence.
On March 25, 2026, EDAP reported an earnings per share (EPS) of -$0.25, falling short of the estimated EPS of -$0.15. Despite this, the company achieved a revenue of approximately $22.2 million, surpassing the estimated $14.7 million. This revenue growth is attributed to a 39% year-over-year increase in HIFU revenue, driven by strong sales of the Focal One® System.
The company's Q4 2025 earnings call, provided insights into its financial performance and strategic direction. EDAP reported a 69% year-over-year growth in Focal One System placements and a 28% increase in U.S. procedures during the fourth quarter. This marks the second consecutive quarter of double-digit growth in procedures, indicating robust demand for their systems.
EDAP's financial metrics reveal a price-to-sales ratio of approximately 1.94 and an enterprise value to sales ratio of about 1.70, suggesting a balanced valuation relative to its sales. The company's debt-to-equity ratio is 0.13, reflecting a conservative approach to debt. Additionally, EDAP maintains a current ratio of 1.54, indicating its ability to cover short-term liabilities with short-term assets.
Despite these positive indicators, EDAP faces challenges with a negative earnings yield and a negative price-to-earnings ratio. This may point to financial difficulties or losses. However, the company remains optimistic, reiterating its 2026 revenue guidance with expectations of HIFU revenue growth between 34% and 45% year-over-year, driven by strong global demand for the Focal One Robotic HIFU.
